US 9,808,455 B2
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
Tsu Tshen Chuang, Essek (GB); Ann Jacqueline Hunter, Hertfordshire (GB); and David John Virley, Essex (GB)
Assigned to Axovant Sciences GmbH, Basel (CH)
Filed by Axovant Sciences GmbH, Basel (CH)
Filed on Jul. 17, 2015, as Appl. No. 14/802,036.
Application 14/802,036 is a continuation of application No. 12/746,968, granted, now 9,084,742, previously published as PCT/EP2008/067225, filed on Dec. 10, 2008.
Claims priority of application No. 0724281.1 (GB), filed on Dec. 12, 2007; and application No. 0724285.2 (GB), filed on Dec. 12, 2007.
Prior Publication US 2015/0320742 A1, Nov. 12, 2015
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 45/06 (2006.01); A61K 31/4523 (2006.01); A61K 31/13 (2006.01); A61K 31/519 (2006.01); A61K 31/4525 (2006.01); A61K 31/00 (2006.01); A61K 31/5513 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 31/00 (2013.01); A61K 31/13 (2013.01); A61K 31/4525 (2013.01); A61K 31/519 (2013.01); A61K 31/5513 (2013.01); A61K 45/06 (2013.01)] 14 Claims
 
1. A method of treating a cognitive memory disorder in a patient in need thereof comprising administering to said patient 20 to 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an acetylcholinesterase inhibitor;
wherein said cognitive memory disorder is selected from the group consisting of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, and dementia associated with mixed Alzheimer's disease and cardiovascular disease.